Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
Crossref DOI link: https://doi.org/10.1186/s12933-015-0279-z
Published Online: 2015-09-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Simó, Rafael
Guerci, Bruno
Schernthaner, Guntram
Gallwitz, Baptist
Rosas-Guzmàn, Juan
Dotta, Francesco
Festa, Andreas
Zhou, Ming
Kiljański, Jacek
Funding for this research was provided by:
Simó
Amylin Pharmaceuticals
AstraZeneca
Bristol-Myers Squibb